S100B and Parkinson disease: S100B polymorphisms and their contributions to the pathogenesis of PD are widely described and tested at the CNS level (Angelopoulou et al., 2021) and, given the gut-brain axis, theories of genesis and propagation of the disease and glial signaling in the axis (Esposito et al., 2017; Borghammer and Berge, 2019; Leclair-Visonneau et al., 2020; Horsager et al., 2022), it is necessary to deepen the evaluation of enteric S100B.